Literature DB >> 2619339

Serum squamous cell carcinoma antigen levels in women with neoplasms of the lower genital tract and in healthy controls.

W Neunteufel1, G Tatra, C Bieglmayer.   

Abstract

Squamous cell carcinoma antigen levels in 74 healthy volunteers, 57 patients with CIN and 91 patients with cervical carcinoma were determined by radioimmunoassay. 5.4% of healthy volunteers were above and all patients with CIN were below 3.0 ng/ml. 63.1% of 65 patients with primary squamous cell carcinoma, 1 out of 7 adenocarcinomas and 68.4% of 19 patients with recurrence of squamous cell carcinoma of the cervix had elevated SCC antigen levels. Elevated posttreatment levels carried a high risk factor of tumor persistence. Increases in SCC antigen levels during follow up usually signified recurrent carcinoma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2619339     DOI: 10.1007/bf00934525

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  11 in total

1.  [SCC antigen: a sensitive and specific tumor marker for squamous cell carcinoma?].

Authors:  W Fischbach; C Rink
Journal:  Dtsch Med Wochenschr       Date:  1988-02-26       Impact factor: 0.628

2.  Radioimmunoassay for tumor-antigen of human cervical squamous cell carcinoma.

Authors:  H Kato; H Morioka; S Aramaki; T Torigoe
Journal:  Cell Mol Biol Incl Cyto Enzymol       Date:  1979

3.  Tumor-associated antigen, TA-4, in the monitoring of the effects of therapy for squamous cell carcinoma of the uterine cervix. Serial determinations and tissue localization.

Authors:  T Maruo; K Shibata; A Kimura; M Hoshina; M Mochizuki
Journal:  Cancer       Date:  1985-07-15       Impact factor: 6.860

4.  [Diagnostic and prognostic tests--requirements from biostatistical viewpoint].

Authors:  K Dannehl; M P Baur
Journal:  Gynakologe       Date:  1983-09

5.  [Clinical significance of tumor associated antigen TA-4 in gynecologic tumors].

Authors:  Y Inoue; G Ueda; M Yamasaki; M Inoue; Y Tanaka; K Hiramatsu; T Nishino; J Saito; Y Abe
Journal:  Nihon Sanka Fujinka Gakkai Zasshi       Date:  1985-06

6.  Immunohistochemical demonstration of tumor antigen TA-4 in gynecologic tumors.

Authors:  G Ueda; Y Inoue; M Yamasaki; M Inoue; Y Tanaka; K Hiramatsu; J Saito; T Nishino; Y Abe
Journal:  Int J Gynecol Pathol       Date:  1984       Impact factor: 2.762

7.  Prognostic significance of the tumor antigen TA-4 in squamous cell carcinoma of the uterine cervix.

Authors:  H Kato; H Morioka; S Aramaki; K Tamai; T Torigoe
Journal:  Am J Obstet Gynecol       Date:  1983-02-01       Impact factor: 8.661

8.  An evaluation of squamous cell carcinoma antigen in patients with cervical squamous cell carcinoma.

Authors:  E K Senekjian; J M Young; P A Weiser; C E Spencer; S E Magic; A L Herbst
Journal:  Am J Obstet Gynecol       Date:  1987-08       Impact factor: 8.661

9.  Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma.

Authors:  H Kato; T Torigoe
Journal:  Cancer       Date:  1977-10       Impact factor: 6.860

10.  Heterogeneous distribution of acidic TA-4 in cervical squamous cell carcinoma: immunohistochemical demonstration with monoclonal antibodies.

Authors:  H Kato; Y Suehiro; H Morioka; T Torigoe; A Myoga; K Sekiguchi; I Ikeda
Journal:  Jpn J Cancer Res       Date:  1987-11
View more
  3 in total

1.  Squamous cell carcinoma antigen as an adjunct tumour marker in primary carcinoma of the lung.

Authors:  P L Cheah; C K Liam; S F Yap; L M Looi
Journal:  J Clin Pathol       Date:  1994-06       Impact factor: 3.411

2.  Posttreatment cut-off levels of squamous cell carcinoma antigen as a prognostic factor in patients with locally advanced cervical cancer treated with radiotherapy.

Authors:  Ryuji Kawaguchi; Naoto Furukawa; Hiroshi Kobayashi; Isao Asakawa
Journal:  J Gynecol Oncol       Date:  2013-10-02       Impact factor: 4.401

3.  Elevated circulating tumor cells and squamous cell carcinoma antigen levels predict poor survival for patients with locally advanced cervical cancer treated with radiotherapy.

Authors:  Yue-Feng Wen; Tian-Tian Cheng; Xiao-Long Chen; Wen-Jin Huang; Hai-Hua Peng; Tong-Chong Zhou; Xiao-Dan Lin; Li-Si Zeng
Journal:  PLoS One       Date:  2018-10-10       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.